ATE551596T1 - Arzneistoffauthentisierung - Google Patents

Arzneistoffauthentisierung

Info

Publication number
ATE551596T1
ATE551596T1 AT04784722T AT04784722T ATE551596T1 AT E551596 T1 ATE551596 T1 AT E551596T1 AT 04784722 T AT04784722 T AT 04784722T AT 04784722 T AT04784722 T AT 04784722T AT E551596 T1 ATE551596 T1 AT E551596T1
Authority
AT
Austria
Prior art keywords
disclosed
product
counterfeiting
order
medicinal
Prior art date
Application number
AT04784722T
Other languages
English (en)
Inventor
James Polli
Stephen Hoag
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE551596T1 publication Critical patent/ATE551596T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3563—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6402—Atomic fluorescence; Laser induced fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Air-Conditioning For Vehicles (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)
  • Materials For Photolithography (AREA)
  • Collating Specific Patterns (AREA)
AT04784722T 2003-09-22 2004-09-22 Arzneistoffauthentisierung ATE551596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50477403P 2003-09-22 2003-09-22
PCT/US2004/030977 WO2005031302A2 (en) 2003-09-22 2004-09-22 Drug authentication

Publications (1)

Publication Number Publication Date
ATE551596T1 true ATE551596T1 (de) 2012-04-15

Family

ID=34392943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784722T ATE551596T1 (de) 2003-09-22 2004-09-22 Arzneistoffauthentisierung

Country Status (4)

Country Link
US (1) US8719043B2 (de)
EP (1) EP1671094B1 (de)
AT (1) ATE551596T1 (de)
WO (1) WO2005031302A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671094B1 (de) 2003-09-22 2012-03-28 University of Maryland, Baltimore Arzneistoffauthentisierung
US20060283931A1 (en) * 2003-09-22 2006-12-21 University Of Maryland, Baltimore Product authentication
US20050225758A1 (en) * 2004-03-23 2005-10-13 Knopp Kevin J Raman optical identification tag
JP4728327B2 (ja) * 2004-05-18 2011-07-20 シルバーブルック リサーチ ピーティワイ リミテッド 取引端末
US7930064B2 (en) 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
US8247018B2 (en) * 2005-06-20 2012-08-21 Authentiform Technologies, Llc Methods for quality control
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
US9058615B2 (en) * 2007-10-02 2015-06-16 Elady Limited Product evaluation system and product evaluation method
US7647193B2 (en) * 2008-01-23 2010-01-12 International Business Machines Corporation Authentication of pharmaceuticals using molecular computational identification
US8626672B2 (en) * 2008-07-23 2014-01-07 I-Property Holding Corp. Secure tracking of tablets
EP2320875B1 (de) * 2008-07-23 2019-07-03 I-Property Holding Corp. Sichere verfolgung von tabletten
US8284386B2 (en) 2008-11-26 2012-10-09 Parata Systems, Llc System and method for verifying the contents of a filled, capped pharmaceutical prescription
US8374965B2 (en) 2008-11-26 2013-02-12 Parata Systems, Llc System and method for verifying the contents of a filled, capped pharmaceutical prescription
US9189728B2 (en) * 2009-07-23 2015-11-17 I-Property Holding Corp. Method for the authentication of dosage forms
DE202009012784U1 (de) * 2009-09-23 2011-02-10 Steinweg, Detlef Vorrichtung zur Kontrolle des Inhalts Medikamente enthaltender Packungseinheiten
SG186283A1 (en) 2010-06-14 2013-01-30 Trutag Technologies Inc System for producing a packaged item with an identifier
CA2832411C (en) 2011-04-06 2020-03-10 Klein Medical Limited Spectroscopic analyser
US20120278096A1 (en) * 2011-04-28 2012-11-01 David Anthony Holness Methods and systems for prescription drug authentication in supply chain and market distribution
US8534543B1 (en) * 2012-05-18 2013-09-17 Sri International System and method for authenticating a manufactured product with a mobile device
US9053364B2 (en) 2012-10-30 2015-06-09 Authentiform, LLC Product, image, or document authentication, verification, and item identification
US20140350946A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Methods for Tracking Workflow in Pharmacies Involving Compound Operations
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
EP2821940A1 (de) 2013-07-03 2015-01-07 Lumiprobe GmbH Binäre Etikettierung
US20160019366A1 (en) * 2014-07-17 2016-01-21 Paul P. Klomp Method for Validation of Pharmaceutical Composition Formulations
WO2016072874A1 (en) 2014-11-07 2016-05-12 Fernando Cruz - Promoções Técnico Cientificas, Unipessoal Lda Method for encoding pharmaceutical solid forms with an authentication code, a bulk powder encoding device and a product certification process
CN107924468A (zh) * 2015-04-23 2018-04-17 I-资产控股集团 泡罩包装中的元件的简单认证
US10330592B2 (en) * 2017-07-21 2019-06-25 Serguei Koulikov Laser absorption spectroscopy isotopic gas analyzer
WO2019169196A1 (en) 2018-02-28 2019-09-06 Tri-Star Technologies Apparatus, system and method for facilitating tracking of consumable pharmaceutical articles
PL427437A1 (pl) * 2018-10-16 2020-04-20 Instytut Biotechnologii I Medycyny Molekularnej Sposób chemicznego znakowania tabletek z wykorzystaniem otoczki
US11094407B2 (en) * 2019-06-13 2021-08-17 International Business Machines Corporation Electronics miniaturization platform for medication verification and tracking

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446299B (sv) * 1978-04-11 1986-09-01 Kureha Chemical Ind Co Ltd Medicinsk komposition innehallande ett derivat av para-aminobensoesyra som aktiv bestandsdel
US5679954A (en) * 1994-11-14 1997-10-21 Soloman; Sabrie Non-destructive identification of tablet and tablet dissolution by means of infared spectroscopy
US6232124B1 (en) * 1996-05-06 2001-05-15 Verification Technologies, Inc. Automated fingerprint methods and chemistry for product authentication and monitoring
GB2313188B (en) * 1996-05-17 1999-10-20 Pfizer Ltd Spectrophotometric analysis
US6490030B1 (en) * 1999-01-18 2002-12-03 Verification Technologies, Inc. Portable product authentication device
GB2347739A (en) * 1999-03-09 2000-09-13 Pfizer Ltd Powder Analysis
WO2001003646A2 (en) 1999-07-14 2001-01-18 Spectral Dimensions, Inc. High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units
EP1204855A1 (de) * 1999-07-16 2002-05-15 Human Genome Sciences, Inc. In-situ überwachung und kontrolle eines biologischen herstellungsprozesses in echtzeit mittels infrarotspektroskopie
FR2804784B1 (fr) * 2000-02-04 2003-04-11 Novatec Procede universel d'identification et d'authentification d'objets, de vegetaux ou d'etres vivants
US6765212B2 (en) * 2001-02-12 2004-07-20 Analytical Spectral Devices, Inc. System and method for combining reflectance data
US6907351B2 (en) * 2001-08-01 2005-06-14 Aventis Animal Nutrition S.A. Customer-based prediction method and system using near infrared reflectance spectra of materials
US7528957B2 (en) * 2001-12-21 2009-05-05 Malvern Instruments Incorporated Spectrometric process monitoring
US6771369B2 (en) * 2002-03-12 2004-08-03 Analytical Spectral Devices, Inc. System and method for pharmacy validation and inspection
US20060015536A1 (en) * 2003-02-10 2006-01-19 Buchanan Bruce R Database and method of use for authenticity verification of pharmaceuticals
EP1670868B1 (de) 2003-09-05 2008-02-13 William Marsh Rice University Fluoreszierende sicherheitstinten und markierstoffe mit kohlenstoffnanoröhrchen
EP1671094B1 (de) 2003-09-22 2012-03-28 University of Maryland, Baltimore Arzneistoffauthentisierung
US20060283931A1 (en) * 2003-09-22 2006-12-21 University Of Maryland, Baltimore Product authentication
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
US9476839B2 (en) * 2009-03-31 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Device and method for detection of counterfeit pharmaceuticals and/or drug packaging

Also Published As

Publication number Publication date
US8719043B2 (en) 2014-05-06
EP1671094B1 (de) 2012-03-28
EP1671094A4 (de) 2010-05-12
WO2005031302A2 (en) 2005-04-07
WO2005031302A3 (en) 2007-07-19
US20070086625A1 (en) 2007-04-19
EP1671094A2 (de) 2006-06-21

Similar Documents

Publication Publication Date Title
EP1671094A4 (de) Arzneistoffauthentisierung
WO2007117867A3 (en) Product authentication
Gewandter et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors
Ritz et al. Benefits and risks of bariatric surgery in patients aged more than 60 years
WO2006119480A3 (en) Website reputation product architecture
NO20074032L (no) Medisinleveringssystem
WO2012011968A3 (en) Method for the authentication of dosage forms
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
WO2007002009A3 (en) Product authentication
ATE537870T1 (de) Periphere nervenfeldstimulation und rückenmarksstimulation
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
AU2003216884A1 (en) Plant extracts and the use thereof
Tacchini et al. Mycochemicals against cancer stem cells
NO20083307L (no) Anvendelse av et ikke-forsapbart ekstrakt fra plantemasse ved behandling av hudaldring
Money et al. Review of under-recognized adjunctive therapies for cancer
EP4442315A3 (de) Lta4a-hemmer zur behandlung oder vorbeugung von hidradenitis suppurativa
Smith A cautious enthusiasm: mystical piety and evangelicalism in colonial South Carolina
SE0403152D0 (sv) Spectroscopic method
Dobi et al. Irinotecan (CPT-11) canonical anti-cancer drug can also modulate antiviral and pro-inflammatory responses of primary human synovial fibroblasts
WO2005076941A3 (en) Separate trading of registered interest and principal of securities system, method and computer program product
ATE499040T1 (de) Vorrichtung zur arzneimittelverabreichung und/oder überwachung des zustandes eines patienten
WO2012099962A3 (en) Pharmaceutical compositions and methods for making and using them
Cho et al. Milnacipran has an antihyperalgesic effect on cisplatin-induced neuropathy
BR112018008556A2 (pt) ?composições farmacêuticas e métodos para tratar ictiose congênita?